Key clinical point : There is a decline in renal function among patients with chronic myeloid leukaemia (CML) treated with tyrosine kinase inhibitors (TKIs).
Major finding : There was a significant reduction between the first and final recorded estimated glomerular filtration rate across all patients, declining by a mean of -12 mL/minute/1.73m 2 over the 10 years of measurement.
Study details : The data come from a retrospective analysis of 50 patients with CML treated with TKI therapy for at least 2 years.
Disclosures: No information on funding was available. The presenting author R Hinton declared no conflicts of interest. The second author S Arami reported relationships with various pharmaceutical companies.
Source: Hinton R et al. Poster. Abstract 053 . BSH 2020. 2020 Nov 9-14.